John R. Regan

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Christopher Pargellis, Liang Tong, Laurie Churchill et al. · Nature Structural Biology · 2002 · 834 citations · Full text

Life Sciences, Immunology, Molecular Biology +15

Pyrazole Urea-Based Inhibitors of p38 MAP Kinase:  From Lead Compound to Clinical Candidate

John R. Regan, Steffen Breitfelder, Pier F. Cirillo et al. · Journal of Medicinal Chemistry · 2002 · 350 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The kinetics of binding to p38 MAP kinase by analogues of BIRB 796

John R. Regan, Christopher A. Pargellis, Pier F. Cirillo et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 111 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Structure−Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-<i>tert</i>-Butyl-2-<i>p</i>-tolyl-2<i>H</i>-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796)

John R. Regan, Alison J. Capolino, Pier F. Cirillo et al. · Journal of Medicinal Chemistry · 2003 · 106 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16

Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis.

Christopher Pargellis, John R. Regan · PubMed · 2003 · 65 citations

Medicine, Pharmacology, Pharmacotherapy +17